See original here:
Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh